Meta-analysis using Bayesian modeling to assess the cardiotoxicity of therapies for advanced prostate cancer
IOSI Oncology Institute of Southern Switzerland – EOC shared a post on LinkedIn:
“New publication!
We’re pleased to share a collaborative article published in European Urology and co-authored by Prof. Silke Gillessen, Medical Director at the IOSI Oncology Institute of Southern Switzerland – EOC.
This systematic review and meta-analysis uses Bayesian modeling to assess the cardiotoxicity of therapies for advanced prostate cancer, focusing on metastatic hormone-sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate-resistant (mCRPC) stages. The findings emphasize that the combination of androgen deprivation therapy + docetaxel + darolutamide presents fewer risks of hypertension and arrhythmias compared to other combinations, offering safer alternatives for treatment.
These findings could help refine treatment strategies to minimize cardiovascular risks while maximizing therapeutic efficacy.
Read the full review here.
Authors: Moez Karim Aziz, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023